Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant778 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,523 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT01461850 | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm(SCORPION) | completed | Phase 3 | 171 | Catholic University of the Sacred HeartOTHER | 1 | Oct 14, 2020 |
| clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02560337 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.(CaTo-ROC) | completed | Phase 2 | 26 | Vejle HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04573933 | Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.(BREIZH-PARPi) | completed | — | 54 | University Hospital, BrestOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02163720 | Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) | completed | — | 101 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01441154 | Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment | completed | — | 16 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2020 | clinicaltrials |
| NCT01787656 | A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus | completed | — | 438 | University of South AlabamaOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01616303 | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | completed | Phase 2 | 97 | Quest PharmaTech Inc.INDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00340210 | Extended Follow-up of Columbia, MO Serum Bank Participants | completed | — | 6,720 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00801320 | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | N/A | 100 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | completed | Phase 1 | 44 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01139957 | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | completed | — | 1,916 | Gynecologic Oncology GroupNETWORK | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02297958 | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma(IFFaLCCO) | completed | — | 28 | Rennes University HospitalOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02121990 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04507191 | PDL1 in Ovarian High Grade Serous Carcinoma | completed | — | 54 | Port Said University hospitalOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT03656809 | Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer | completed | — | 125 | NYU Langone HealthOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT03430518 | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | completed | Phase 1 | 9 | Amy TierstenOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03082976 | Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region(PREDICT) | completed | — | 108 | AstraZenecaINDUSTRY | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02714621 | MR-HIFU for Recurrent Gynaecological Cancer(HIFU-Gynae) | completed | N/A | 31 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02984423 | FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study(FLABRA) | completed | — | 471 | AstraZenecaINDUSTRY | 6 | Jul 10, 2020 | clinicaltrials |
| NCT04461457 | Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | completed | Early Phase 1 | 12 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04135521 | Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer | completed | — | 50 | Far Eastern Memorial HospitalOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT02144311 | Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics | completed | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT03543462 | Diaphragmatic Resection And Gynecological Ovarian Neoplasm(DRAGON) | completed | Phase 4 | 88 | Catholic University of the Sacred HeartOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02090582 | H.O.P.E: Helping Ovarian Cancer Patients Cope | completed | N/A | 47 | Duke UniversityOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT03175991 | Gynacological Imaging Reporting and Data System in Ovarian Masses by Ultrasonography | completed | — | 123 | Assiut UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00849199 | Cancer Screening and Prevention Program for High Risk Women | completed | — | 1,452 | NYU Langone HealthOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | completed | Phase 1 / Phase 2 | 51 | COL George Peoples, MD, FACSFED | 1 | May 4, 2020 | clinicaltrials |
| NCT01370122 | Pelvic Floor Disorders in Survivors of Gynecologic Malignancies | completed | — | 225 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00341458 | Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics | completed | — | 6,086 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2020 | clinicaltrials |
| NCT02529150 | WISER After Ovarian Cancer - Exercise Pilot Study | completed | N/A | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT00030446 | Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00003892 | ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer | completed | Phase 2 | 22 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 6, 2020 | clinicaltrials |
| NCT00006036 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 14 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00010179 | Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 81 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients(CORAIL) | completed | Phase 3 | 442 | PharmaMarINDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 3 | 819 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT03069872 | A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer | completed | N/A | 490 | University of AarhusOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT04284631 | Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. | completed | — | 54 | Port Said University hospitalOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT01536054 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Oct 19, 2020source: clinicaltrials